Browse All
Displaying 1 - 3 of 3
Author:DeLuca, John Cohen, Jeffrey A. Cree, Bruce A. C. Cheng, Chun-Yen Sheffield, James K. Riolo, Jon V. Silva, Diego Comi, Giancarlo Kappos, Ludwig
Session Name:P6: MS Clinical Trials
Topic:MS and Inflammatory Disease
Program Number:P6.001
Author Institution:Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, San Francisco, CA Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ Vita-Salute San Raffaele University, and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
Author:Kister, Ilya Benedict, Ralph Comi, Giancarlo Cutter, Gary Oreja Guevara, Celia Clinch, Susanne Kuenzel, Thomas Dirks, Petra Vermersch, Patrick
Program Number:P6.010
Author Institution:New York University Langone Medical Center, Multiple Sclerosis Comprehensive Care Center, New York, NY, USA, Passaic, NJ Jacobs School of Medicine and Biomedical Sciences, Department of Neurology, University of Buffalo, NY, USA, Buffalo, NY Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL Hospital Clinico San Carlos, Madrid, Spain, Madrid, Spain Roche Products Ltd, Welwyn Garden City, United Kingdom F. Hoffmann-La Roche Ltd, Basel, Switzerland, Welwyn Garden City, United Kingdom F. Hoffmann-La Roche Ltd, Basel, Switzerland, Grenzach-Wyhlen, Germany Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, Lille, France
Author:Naismith, Robert T. Cohen, Jeffrey A. Bar-Or, Amit Comi, Giancarlo Selmaj, Krzysztof W. Hartung, Hans-Peter Sheffield, James K. Krakovich, Anthony Cheng, Chun-Yen Reardon, Jennifer Riolo, Jon V. Silva, Diego Cree, Bruce A. C.
Session Name:P7: MS Therapeutics 1
Program Number:P7.013
Author Institution:Washington University School of MedicineWashington University School of Medicine, St Louis, Missouri, St Louis, MO Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of PennsylvaniaCenter for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelph Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy Center for Neurology, Lódz, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Olsztyn, Poland Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf Germany Brain and Mind Centre, University of Sydney, Australia Department of Neurology, Medical University of Vienna, Austria and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Germany Bristol Myers Squibb, Princeton, New Jersey, Princeton, PA Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ Weill Institute for Neurosciences, Department of Neurology, University of California San FranciscoWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA
